Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide

European Journal of Cancer Care

Volumn 19, Issue 2, 2010, Pages 200-204

  Montella, L ^a   Addeo, R ^a   Guarrasi, R ^a   Cennamo, G ^a   Faiola, V ^a   Capasso, E ^a   Caraglia, M ^b   Del Prete, S ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Breast cancer; Chemotherapy; Palliative care; Polyethylene glycol colony stimulating factors; Supportive care; Symptoms

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; BREAST NEOPLASMS; CHEMICALLY INDUCED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FILGRASTIM; HUMANS; MIDDLE AGED; NEUTROPENIA; TAXOIDS; TREATMENT OUTCOME; GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS;

EID: 76949105055     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.01004.x     Document Type: Article

References (22)

1. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. British Medical Journal 2005, 330:217-222.
2. Chan S, Friedrich K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J. Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology 1999, 17:2341-2354.
3. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Seminars in Oncology 2003, 30(13):24-30. Suppl
4. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer. A report of the Clinical Screening Group of the EORTC. Annals of Oncology 1996, 7:165-171.
5. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology 2002, 20:727-731.
6. Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 2006, 42:2433-2453.
7. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology 2007, 25:3158-3167.
8. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. The Journal of the National Comprehensive Cancer Network 2005, 3:557-571.
9. Martin M, Pienkowski T, Mackey J, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C. Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine 2005, 352:2302-2313.
10. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C, Roset M, Anton A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, Lopez-Vega JM, Munoz M, Mel JR. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology 2006, 17:1205-1212.
11. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003, 23(2):3S-8S. Pt
12. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Current Pharmaceutical Design 2004, 10:1235-1244.
13. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. Journal of Managed Care Pharmacy 2007, 13:337-348.
14. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noël DR, Al-Tweigeri T, Tonkin K, North S, Azli N, Riva A. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 2001, 19:314-321.
15. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. The Oncologist 2007, 12:484-494.
16. Rader M. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology 2006, 20:16-21.
17. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncology Reports 2003, 10:715-724.
18. Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clinical Breast Cancer 2002, 3:333-340.
19. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. Recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 24:3187-3205.
20. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Fiueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2005, 23:1178-1184.
21. Von Minckwitz G, Blohmer J, Lohr A, Raab G, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Kaufmann M. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2005, 23(16). Suppl, Part I of II, June 1 Supplement), 8008
22. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Journal of Clinical Oncology 2003, 21:514-519.